東莨菪鹼市場：按配方、分銷渠道、地區 - 規模、份額、前景、機會分析，2022-2030

東莨菪鹼是一種從紫荊屬植物中提取的生物鹼藥物，用於治療噁心和暈動病，以及在眼科手術中擴張瞳孔。東莨菪鹼屬於一類稱為抗膽鹼能藥的藥物。東莨菪鹼是一種從茄科植物中分離出來的托烷類生物鹼，與阿托品和莨菪鹼一樣，在結構上模仿天然神經遞質乙□膽鹼。該藥通過抑制神經遞質乙□膽鹼的活性，刺激大腦中引起噁心和嘔吐、肺部、胃腸道和泌尿道等肌肉不自主運動的部位，並發揮其作用。東莨菪鹼在醫療環境中用作鎮靜劑和催眠劑，有時與嗎啡一起緩解疼痛。東莨菪鹼也被規定為“標籤外”，以緩解與抑鬱症、哮喘、戒菸輔助和化療相關的噁心。美國國家生物技術信息中心2019年7月公佈的數據顯示，東莨菪鹼是一種抗膽鹼能顛茄生物鹼，通過競爭性抑制毒蕈鹼受體影響副交感神經功能，對乙□膽鹼有反應，但對膽鹼無反應，作用於非受神經支配的平滑肌。東莨菪鹼是一種貼劑配方，可持續釋放 3 天，並且在尿液中可檢測到 108 小時。東莨菪鹼在閉角型青光眼中是禁忌的，由於其升高眼壓的作用，開角型青光眼患者必須謹慎使用。

市場動態

全球患有壓力和焦慮症的人口不斷增長，預計將推動全球東莨菪鹼市場的增長。例如，2022年3月，GOQii印度壓力與心理健康調查公佈的數據顯示，2021年有29.31%的印度人患有抑鬱症。 10個患有胃腸道疼痛的人中有7個將其歸因於壓力。根據美國國家生物技術信息中心的數據，美國約有 12% 的成年人患有腸易激綜合徵，原因是在 COVID-19 大流行造成經濟損失後壓力增加。女性患腸易激綜合徵的可能性是男性的兩倍。多達四分之三的腸易激綜合徵患者將壓力作為可靠來源。神經系統控制腸道並對心理壓力作出反應。

本研究的主要特點

• 本報告對全球東莨菪鹼市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。
• 解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
• 該研究還提供了有關市場驅動因素、抑制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
• 它根據以下參數描述了全球東莨菪鹼市場的主要參與者 - 公司亮點、產品組合、關鍵亮點、財務業績和戰略
• 本研究涵蓋的主要公司包括 Baxter International Inc.、GlaxoSmithKline plc. Novartis AG、Perrigo Company plc.、Caleb Pharmaceuticals, Inc.、Myungmoon Pharma Co. LTD.、Alchem International、Phytex Australia、Centroflora -Cms、澳大利亞生物鹼和精細化工公司
• 本報告中的見解將使營銷人員和企業高管能夠就其未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。可能
• 全球東莨菪鹼市場報告面向行業內的各種利益相關者，包括投資者和供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過在分析全球東莨菪鹼市場時使用的各種策略矩陣輕鬆做出決策。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第2章市場展望

• 舉報內容
  • 市場定義和範圍
• 執行摘要
  • 市場快照：按劑型
  • 市場快照：按分銷渠道
  • 市場概況：按地區劃分
• 連貫的機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

• 市場動態
  • 驅動程序
  • 約束因素
  • 市場機會
• 影響分析
• 市場趨勢
• 主要發展狀況
• 流行病學
• 歷史概覽
• 藥品的盈利潛力
• 搬運工五力
• PEST 分析

第 4 章東莨菪鹼全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第 5 章全球東莨菪鹼市場，按配方，2017-2030 年

• 藥片
• 糖漿
• 注入
• 補丁
• 其他

第 6 章全球東莨菪鹼市場，按分銷渠道，2017-2030 年

• 醫院藥房
• 零售藥房
• 在線藥店

第 7 章。2017-2030 年東莨菪鹼全球市場，按地區分列

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海合會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第 8 章競爭格局

• 熱圖分析
• 公司簡介
  • Baxter International Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Perrigo Company plc.
  • Caleb Pharmaceuticals, Inc.
  • Myungmoon Pharma Co. LTD.
  • Alchem International
  • Phytex Australia
  • Centroflora-Cms
  • Alkaloids of Australia
  • Fine Chemicals Corporation

第9章 章節

• 參考文獻
• 調查手法

Scopolamine is an alkaloid drug extracted from a plant called henbane to treat nausea and motion sickness and further to dilate the pupil in ophthalmic procedures. Scopolamine belongs to a class of drugs called anticholinergic. Scopolamine is a tropane alkaloid isolated from members of the Solanaceae family of plants, similar to atropine and hyoscyamine, all of which structurally mimic the natural neurotransmitter acetylcholine. It works by blocking the activity of the neurotransmitter acetylcholine, which stimulates the part of the brain that triggers nausea and vomiting, involuntary muscle movement in the lungs, and the gastrointestinal and urinary tracts. Scopolamine is also used in medicine as a sedative or hypnotic and sometimes with morphine to relieve pain. Scopolamine has also been prescribed 'off label' for depression, asthma, as a smoking-cessation remedy, and to relieve the nausea that accompanies chemotherapy. According to data published by National Center for Biotechnology Information, in July 2019, Scopolamine is an anticholinergic belladonna alkaloid that, through competitive inhibition of muscarinic receptors, affects parasympathetic nervous system function and acts on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Formulated as a patch, scopolamine is released continuously over three days and remains detectable in urine over a period of 108 hours. Scopolamine is contraindicated in angle-closure glaucoma and should be used with caution in patients with open-angle glaucoma due to scopolamine's ability to increase intraocular pressure.

Market Dynamics

Increasing global population suffering from stress and anxiety disorders is expected to fuel growth of the global scopolamine market. For instance, in March 2022, according to data published by the GOQii survey on the stress and mental health status of Indians, the GOQii Survey indicates that 29.31% of Indians were suffering from depression in 2021. Stress was the cause for seven out of ten patients suffering from gastrointestinal pain. According to the National Center for the Biotechnology Information around 12 percent Trusted Source of adults in the United States have Irritable bowel syndrome due to increasing stress after economic loss in covid-19 pandemic. Women are twice as likely to have Irritable bowel syndrome as men. As many as three-quarters Trusted Source of people with Irritable bowel syndrome report stress. The nervous system controls the gut and also responds to psychological stress.

Key features of the study:

• This report provides an in-depth analysis of the global scopolamine market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global scopolamine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global scopolamine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global scopolamine market

Detailed Segmentation:

• Global Scopolamine Market, By Dosage Form:
  • Tablet
  • Syrup
  • Injection
  • Patch
  • Others
• Global Scopolamine Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Scopolamine Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Baxter International Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
  • Novartis AG
  • Perrigo Company plc.
  • Caleb Pharmaceuticals, Inc.
  • Myungmoon Pharma Co. LTD.
  • Alchem International
  • Phytex Australia
  • Centroflora-Cms
  • Alkaloids of Australia
  • Fine Chemicals Corporation

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Epidemiology
• Historical Overview
• Revenue Potential of Drugs
• PORTER'S Five Forces
• PEST Analysis

4. Global Scopolamine Market - Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Scopolamine Market, By Dosage Form, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Tablet
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Syrup
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Injection
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Patch
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Scopolamine Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Scopolamine Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Baxter International Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Market Strategies
  • GlaxoSmithKline plc
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Market Strategies
  • Novartis AG
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Perrigo Company plc.
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Caleb Pharmaceuticals, Inc.
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Myungmoon Pharma Co. LTD.
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Alchem International
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Phytex Australia
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Centroflora-Cms
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
  • Alkaloids of Australia
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Fine Chemicals Corporation
• Company Overview
• Dosage Form Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies

9. Section

• References
• Research Methodology
• About Us and Sales Contact